Cell Therapy Manufacturing Market CAGR of 9.50% by 2035, Due To The Rising Demand for Effective Cell Therapies | Roots Analysis

According to our latest market report "Cell Therapy Manufacturing Market" by Type of Cell Therapy, Source of Cells, Scale of Operation, Type of Manufacturer and Geography: Industry Trends and Global Forecasts, Till 2035", the global cell therapy manufacturing market size is projected to reach USD 13.8 billion by 2035 from USD 5.5 billion in 2025 and USD 4.9 billion in 2024, growing at a CAGR of 9.50% in the forecast period 2025-2035.

To request quote of this report, please visit:
https://www.rootsanalysis.com/reports/cell-therapy-manufacturing/request-quote.html

Various preclinical as well as clinical-stage cell therapies are currently being evaluated by both start-ups and well-established players across different geographies. These therapies are presently being investigated in different research studies (preclinical and clinical) and have also been approved in various jurisdictions.

Based on the type of cell therapy, the market is segmented into T cell therapies, NK cell therapies, dendritic cell therapies and stem cell therapies.

1. The T cell therapies segment captures the largest revenue share of close to 80% in the cell therapy manufacturing market, in 2024.
2. The dendritic cell therapies segment is anticipated to be the fastest growing segment in this industry, with an annualized rate (CAGR) of 11.1% during the forecast period.

Based on the source of cells, the market is segmented into autologous, allogeneic and unspecified.

1. The autologous segment captures the largest revenue share of close to 65% in the cell therapy manufacturing market, in 2024.
2. The autologous source of cells segment is likely to dominate the market, till 2035; this can be attributed to various factors including reduced risks of rejection from the host, readily available and the current approval rates are higher for these autologous therapies.

Based on the scale of operation, the market is segmented into clinical and commercial scales.

1. The clinical operations segment captures the largest revenue share of over 75% in the cell therapy manufacturing market, in 2024.
2. The commercial scale of operations is anticipated to be the fastest growing segment in this industry, with an annualized rate (CAGR) of 13.4% during the forecast period.

To request a sample copy / brochure of this report, please visit
https://www.rootsanalysis.com/reports/cell-therapy-manufacturing/request-sample.html

Based on the type of manufacturer, the market is segmented into in-house manufacturers and contract manufacturing organizations.

1. The contract manufacturing organizations segment captures the largest revenue share of close to 70% in the cell therapy manufacturing market, in 2024.
2. The in-house manufacturers segment is anticipated to be the fastest growing segment in this industry, with an annualized rate (CAGR) of 11% during the forecast period.

Based on the geography, the market is segmented North America, Europe, Asia Pacific and Rest of the World
1. The North America segment captures the largest revenue share of close to 45% in the cell therapy manufacturing market, in 2024.
2. This trend is likely to remain the same in the coming years, as the number of approved advanced therapy medicinal products is likely to be on the rise within this region.

Cell Therapy Manufacturing Market Regional Outlook
Based on the key geographical regions, the cell therapy manufacturing market can be segmented into four major regions, including North America, Europe, Asia-Pacific and rest of the world. Led by the US, North America is anticipated to capture the majority share of the cell therapy manufacturing market in 2024. This trend is likely to remain the same in the upcoming future, this can be attributed to the increasing number of approved ATMPs in this region. Further, Asia-Pacific and rest of the world is anticipated to rapidly increase their cell therapy manufacturing operations to emerge as the growing segment of the market.

Key Report Takeaways
1. Currently, more than 190 industry players are engaged in the cell therapy manufacturing industry, across the globe
2. Presently, the cell therapy manufacturing market features the presence of nearly 75 non-industry players, worldwide
3. A comprehensive set of company profiles of prominent / emerging players offers valuable insights into their current strategic focus and future initiatives, empowering stakeholders with crucial information
4. At present, more than 2,000 clinical trials are currently being conducted across various stages of development for evaluating cell therapies
5. Presently, over 70 automation technologies are currently available for the manufacturing of cell therapies to minimize manual interventions
6. The cell therapy manufacturing domain is poised to grow at the CAGR of 10%; the opportunity is well distributed across different types of cell therapies, sources of cells, scale of operation, type of manufacturer and geography

Browse Full Report Description + Research Methodology + Table of Content + Infographics here:
https://www.rootsanalysis.com/reports/cell-therapy-manufacturing/285.html

Cell Therapy Manufacturing Market Key Players
The cell therapy manufacturing market report also includes profiles of key players that manufacture cell therapies include AGC Biologics, BioNTech Innovative Manufacturing Services, Cell and Gene Therapy Catapult, Cell Therapies, Center for Cell and Gene Therapy, Baylor College of Medicine, Centre for Cell Manufacturing Ireland, National University of Ireland, Charles River Laboratories, Clinical Cell and Vaccine Production Facility, University of Pennsylvania, FUJIFILM Cellular Dynamics, Guy's and St. Thomas' GMP Facility, Guy's Hospital, KBI Biopharma, Laboratory for Cell and Gene Medicine, Stanford University, Lonza, MEDINET, Minaris Regenerative Medicine, Molecular and Cellular Therapeutics, University of Minnesota, Newcastle Cellular Therapies Facility, Newcastle University, Nikon CeLL Innovation, Rayne Cell Therapy Suite, King's College London, RoslinCT, Scottish National Blood Transfusion Services, Cellular Therapy Facility, Scottish Centre for Regenerative Medicine, Sydney Cell and Gene Therapy, Thermo Fisher Scientific, WuXi AppTec.

Contact Details
Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com
Website: https://www.rootsanalysis.com

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

This release was published on openPR.